Skip to main content
logo
Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
190.00
-31.20 (-14.10%)
Jul 30, 2026, 2:15 PM HKT

Duality Biotherapeutics Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '25 Dec '24 Dec '23
Revenue
1,8521,8521,9411,787
Revenue Growth
-14.68%-4.61%8.66%-
Gross Profit
589.09589.09784.671,359
Operating Income
-460.12-460.12-187.04736.27
Net Income
-2,595-2,595-1,050-357.51
Earnings Per Share
-39.82-39.82-131.30-44.69
EPS Growth
----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '25 Dec '24 Dec '23
Cash & Investments
3,3803,3801,3971,136
Total Debt
149.78149.785.295.32
Net Cash (Debt)
3,2303,2301,3921,131
Net Cash Growth
-11.24%132.13%23.07%-
Net Cash Per Share
49.5849.58173.96141.35

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '25 Dec '24 Dec '23
Operating Cash Flow
194.58194.58285.78816.34
Capital Expenditures
-11.5-11.5-4.08-11.28
Free Cash Flow
183.08183.08281.7805.05
Free Cash Flow Growth
-73.57%-35.01%-65.01%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingDec '25 Dec '25 Dec '24 Dec '23
Gross Margin
31.81%31.81%40.42%76.06%
Operating Margin
-24.85%-24.85%-9.63%41.21%
Pretax Margin
-140.13%-140.13%-52.26%-11.32%
Profit Margin
-140.13%-140.13%-54.11%-20.01%
FCF Margin
9.89%9.89%14.51%45.06%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023
Period EndingJul '26 Dec '25 Dec '24 Dec '23
P/FCF Ratio
98.18130.88--
PS Ratio
9.7112.94--